Cystinosis is a lysosomal storage disease caused by mutations in CTNS, encoding a cystine transporter, and in its severest form is characterized by cystine accumulation, renal proximal tubule dysfunction and kidney failure. Cystinosis is treated with the cystine-depleting drug cysteamine, however this only slows progression of the disease and there is an urgent need for better treatments. Here, we have generated and characterized the first human induced pluripotent stem cell (iPSC) and kidney organoid models of cystinosis. These models exhibit elevated cystine and cysteine levels, enlarged lysosomes and a block in basal autophagy flux.
The current treatment for cystinosis is life-long therapy with cysteamine, a molecule that cleaves the cystine disulphide bond to produce mixed disulphides that can escape the lysosome through alternative transporters. 8, 9 However, cysteamine only slows the progression of renal injury and kidney transplantation is inevitably required later in life. 9, 10 As a result, there remains a pressing need to develop more effective therapies for cystinosis.
While there is not yet a complete understanding of the pathogenesis of cystinosis, several lines of evidence indicate that cystine loading causes lysosomal enlargement, impaired proteolysis and delayed fusion with cargo-loaded vesicles. [11] [12] [13] [14] Other cellular features of cystinotic cells that are variably present in different cell types include reduced ATP and glutathione levels, mitochondrial damage, oxidative stress, increased apoptosis, and proximal tubule cell dedifferentiation. 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] In addition, cystinotic proximal tubule cells display decreased expression of the endocytic receptors megalin and cubulin, and impaired megalin recycling. 11, 12 Defects in macroautophagy (herein referred to as autophagy) are also found in cystinotic cells.
Autophagy involves the sequestration of a portion of the cytoplasm by a double-layered membrane known as an autophagosome, followed by fusion with a lysosome to form an autolysosome. 28 This final step can be modulated by bafilomycin A1, an inhibitor of autophagolysosome acidification that disrupts autophagosome-lysosome fusion. 29 Under, resting conditions, basal levels of autophagy are required in a 'house-keeping' capacity to degrade long-lived and ubiquitinated proteins, N-linked glycans, damaged organelles such as mitochondria, and to dampen certain pathways such as inflammatory, Notch and Wnt signaling. [30] [31] [32] Under stress conditions, such as starvation, autophagy is greatly upregulated to ensure metabolically useful molecules are recycled in order to maintain cellular homeostasis.
While starvation-induced autophagy is normal in cystinotic cells, 33 basal autophagy flux is reduced in a number of cystinotic cell lines, resulting in a build-up of autophagosomes that frequently contain mitochondria. 26, 33, 34 In addition, the separate pathway of chaperonemediated autophagy, in which specific cytosolic proteins are directly delivered across the lysosomal membrane for degradation, is also defective in fibroblasts from the Ctns-knockout mouse. 33 More recently, CYSTINOSIN has been implicated in modulating the mTORC1 signalling pathway, which integrates both intracellular and extracellular signals and serves as a core regulator of cellular metabolism, proliferation, survival and autophagy. 35 mTORC1 switches between active and inactive states in response to nutrient availability. 36, 37 Inhibition of mTORC1 by a class of drugs that include Everolimus, which is used clinically as an immunosuppressant and anti-cancer agent, results in activation of autophagy. 38, 39 CYSTINOSIN physically interacts with mTORC1 binding partners, including the vacuolar ATPase proton pump and the Ragulator complex, which are necessary for mTORC1 activation by amino acids 40 . Loss of CYSTINOSIN function in conditionally immortalised human and mouse proximal tubule cell lines leads to a reduction in mTORC1 activity as well as delayed reactivation following a return to amino acid rich conditions. 40, 41 One of the challenges of the cystinosis field is a lack of good human-based cell culture models.
To address this, we generated patient-specific and CRISPR/Cas9-edited cystinotic induced pluripotent stem cells (iPSCs). These cells have the advantages of being a renewable source of non-immortalised cystinotic cells and can be differentiated into numerous tissues, including kidney organoids. Our analysis of CTNS-iPSCs and kidney organoids revealed increased cystine and cysteine levels, enlarged lysosomes, abnormal basal autophagy flux and altered gene expression compared to healthy controls, consistent with modelling key aspects of the cystinotic phenotype. We further discovered that some of these defects can be rescued by treatment with cysteamine or Everolimus alone, but that combination therapy was the most efficacious. These results suggest that a cysteamine/Everolimus combination therapy holds tremendous therapeutic potential to improve the treatment, and health outcomes, of individuals with cystinosis.
Materials and Methods: iPSC lines and maintenance
All work was carried out with the approval of the University of Auckland Human Participants Ethics Committee (UAHPEC 8712), Human and Disability Ethics Committee (17/NTA/204) and biosafety approval (GMO05). The CRL1502 clone C32 and the cystinosis iPSC lines were developed in Dr Wolvetang's 42 and Dr Davidson's laboratory, respectively. For the patientderived cystinosis lines (CTNS -/-), adipose-derived mesenchymal cells were derived from an individual with nephropathic cystinosis using a lentiviral doxycycline-inducible polycistronic vector containing OCT4, SOX2, CMYC, KLF4 and NANOG. Five CTNS -/-iPSC lines were generated, three of which (36, 108, 157) displayed a normal karyotype (determined by LabPLUS, New Zealand). These lines were confirmed to be pluripotent based on immunostaining of cell surface markers (SSEA-4, TRA-1-6-, TRA-1-81) and the formation of teratomas following transplantation of 1x 10 6 cells under the kidney capsule of 8 wk old SCID mice (n=3 mice per line), according to established procedures 43 . All iPSC lines were cultured on LDEV-free hESC-qualified Geltrex-coated tissue culture dishes in mTeSR1 (Stemcell Technologies) medium supplemented with 1% penicillin-streptomycin, and 2.5 μg/mL Plasomcin (InvivoGen). At ~70% confluence, cells were dissociated using 1/3 Accutase in DPBS. Cells were scraped from the dish, pelleted at 800 rpm for 5 min and resuspended in mTeSR1 plus 5μM Y27632 dihydrochloride (Stemcell Technologies) for the first 24 hours to facilitate cell survival. Unless otherwise stated, all drug treatments (1 μM Cysteamine; Sigma, 100 nM Everolimus; RAD001 Selleckchem, 30 mM 3-methyladenine; Sigma, 50 mM Sucrose; Sigma) were added to cell culture medium and incubated with the cells for 24 hrs.
For starvation/refeeding experiments, cells were grown on 10 cm culture dishes until 70% confluent and incubated for 2 hrs in fresh culture medium (basal condition). For starvation, cells were washed twice in phosphate-buffered solution (PBS) and incubated in Hank's balanced salt solution (HBSS) for 1 hr. Refeeding was performed by incubating cells in normal culture medium for the indicated time points.
Generation of CTNS knockout lines by gene editing
Guide (g) RNA pairs targeted to introduce a 257 bp deletion in exon 8 and 9 of the CTNS gene were designed using RGEN and COSMID online tools 44, 45 (http://www.rgenome.net/casdesigner/; http://crispr.bme.gatech.edu/). Knockout efficiencies were first evaluated in HEK293 cells. Optimal gRNAs (gRNA_ex81.0: 5'-TCCACCCCCTGCAGTGTCATTGG-3'; gRNA_ex93.0: 5'-GCGTGAGGACAACCGCGTGCAGG-3') were cloned into the pSPCas9(BB)-2A-GFP plasmid (Addgene 48138) and introduced into CRL1502 iPSCs by reverse transfection using TransIT-LT1 (Mirus Bio). GFP positive cells were isolated 48 hrs later by flow cytometric sorting and 8,000 cells were plated on a 10 cm Geltrex-coated dish into pre-warmed mTeSR1 containing 5 μM Y27632. Medium changes were carried out daily using mTeSR1 without Y27632. Single colonies were manually picked when they reached a suitable size (~10 days post plating), clonally expanded and screened for biallelic deletions 
Generation of cystinotic kidney organoids
We used an in-house developed protocol to convert iPSCs into kidney organoids 46 and incubated with secondary antibodies ( Supplemental Table S3 ) at 1:500 dilution in the blocking solution for 2 hrs at RT. Cells were incubated with 10 μg/mL Hoechst 33258 for 5 mins, washed 2 x TBST and mounted with Prolong Gold (Thermo Fisher) before imaging.
Cells were imaged using Zeiss LSM710 confocal microscope.
Magic Red TM -Cathepsin B staining
iPSC imaging assays were set up a day before by seeding cells onto Geltrex coated 35mm Fluro dishes (WPI). Prior to staining, cells were washed 1 x DPBS. Cells were incubated for 1 hr with 26x MR-Cathepsin B in mTeSR1. Hoechst 33258 was added for the final 15 mins. Once staining was completed the dyes were washed off with 1 x DPBS and the cells were fixed with 4% PFA for 10mins. Images were taken using Zeiss LSM710 confocal microscope.
Transmission Electron Microscopy
Samples were fixed in 2.5 % glutaraldehyde and 0.1 M phosphate buffer pH 7.4 (dissociated iPSCs or whole kidney organoids) at 4ºC, and kept in the fixative until processing. Samples were washed 3 x 0.1 M phosphate buffer for 10 min, then fixed in 1% osmium tetroxide in 0.1 M phosphate buffer for an hour at RT and washed twice in 0.1 M phosphate buffer for 5 min.
The samples were then dehydrated in a graded series of ethanol washes 10 min each at RT (50%, 70%, 90% and twice 100%), following with 2 x propylene oxide wash for 10 min at RT.
The samples were then infiltrated with a graded series of propylene oxide:resin mix (2:1, 1:1, 1:2) for 30 minutes each, before being imbedded in freshly made pure resin overnight. The next day the samples were placed into molds and polymerized at 60ºC for 48 hrs. All washes were performed on a rocker. Sectioned samples were imaged using Tecnai™ G² Spirit Twin transmission electron microscope.
Transient Transfection of kidney organoids:
Organoids were cultured as described above until the day of interest. Organoids were first dissociated by incubating them in 100 μl TrypLE Express (gibco) at 37°C for up 10 mins. Once dissociated cells are centrifuged at 800 g for 5 min and resuspended in stage 2 media and reverse transfected using TransIt-LT1. and analysed using image J software.
Image analysis of lysosomes and fluorescent puncta
Magic Red TM 63x magnification confocal raw images (~10 random fields per condition) were analysed using Image J analysis software. Nuclei were manually counted. To obtain a crosssectional area of the enlarged vesicles, particle analysis was performed and the number of vesicles >10 μm 2 were determined per field. Data were expressed as average number of enlarged vesicles per cell and statistically analysed. For the measurement of autophagic puncta, cells were transfected with the LC3-mCherry-GFP vector and imaged by confocal microscopy (10 random fields per condition containing ~1-3 cells in 3 independent experiments) and analysed using Image J. Nuclei and red and yellow puncta were manually counted and the percentage of each puncta per cell was calculated.
Mass Spectrometry
Cells were lysed on ice with cold 50% acetonitrile and centrifuged at 16,000g for 10 min at 4°C. The supernatant was transferred to a cold Eppendorf tube and stored at -80°C until samples were ready to be processed. 
RNA extraction, cDNA synthesis and quantitative PCR analysis
Cells were first washed 1 x PBS before being lysed in GENEzol for 5 mins. RNA was extracted using GENEzol TM TriRNA Pure kit (Geneaid). cDNA was synthesised using qScript cDNA SuperMix (Quanta). For quantitative (q) PCR, PerfeCTa SYBR Green FastMix (Quanta) was used. qPCR was performed on a QuantStudio 6 Flex Real-Time PCR machine. Primers used are listed in Supplemental Table S1 . Samples were normalised to HPRT1 and CREBP expression. Gene expression was calculated using the ddCt method. 48 Error bars represent standard deviation from technical triplicates.
RNA-Sequencing and analysis
Total RNA from 4 samples per iPSC line were prepared using the GENEzol TM TriRNA Pure kit. The quality (RIN), concentration and purity (OD260/230 and OD260/280) of the RNA was determined on Bioanalyser (RNA nano chip), Qubit and Nanodrop instruments. Library preparation and sequencing were performed commercially (New Zealand Genomics Limited, Otago). Libraries were prepared using the TruSeq standard total RNA kit with standard protocols (Illumina). 2 x 125bp paired-end sequencing was performed on an Illumina HiSeq 2500 sequencer. Reads were adapter filtered and quality trimmed using BBDuk version 37.75
(1) with a quality cut-off of phred=10 (trimq=10) and to reduce the potential mapping errors any reads less than 50bp after trimming were removed. QC filtered reads were mapped to the Human genome (GRCh38) downloaded from ENSEMBL (www.ensembl.org/Homo_sapiens/Info/Index) using HISAT2 (version 2.0.5) in stranded mapping mode (-rna-strandness RF). Read counts were generated from the alignment files using HT-Seq (version 0.6.0) under the Union mode and strand option set to "reverse". DESeq2
(2) was used to generate differential expression calls and statistics for control versus knockout comparison based on the observed read counts for each gene. Expression changes were declared significant for q-value < 0.05. Heatmaps were generated in R using the pheatmap_1.0.8 package. GO terms enrichments were analysed using the R package goseq (version 1.22). Enrichment was tested for all differentially expressed genes with an FDR (False Discovery Rate) corrected p-value less than 0.05. The GO terms themselves were also FDR corrected at the same rate.
Statistical analysis
Data are presented as the mean ± SEM. GraphPad PRISM software version 7 (GraphPad Software) was used for all statistical analyses. The statistical significance of the differences between two groups was calculated using an unpaired Student's t-test. For between 3 or more groups one-way Anova was used. A p value <0.05 was considered to be statistically significant.
Results:

Generation of CTNS-iPSC lines
To generate patient-specific CTNS-iPS cells, adipose-derived mesenchymal cells were grown from a fat sample from a nephropathic cystinosis patient undergoing renal transplantation.
Exon sequencing determined that the individual was compound heterozygote for two previously described CTNS mutations: a 57 kb deletion and a L158P missense mutation in exon 8 2 . The mesenchymal cells were reprogrammed into iPSCs and three CTNS -/lines, referred to as 36, 108, 157, possessed normal karyotypes (results not shown). All three lines stained positive for the pluripotency markers alkaline phosphatase, SSEA-4, Tra-1-60 and Tra-1-81, and gave rise to teratomas containing tissues from all three germ layers ( Figure 1A , B and D, data for CTNS -/-36 shown). Re-expression of endogenous OCT4, NANOG, SOX2, CMYC and KLF4 was confirmed by qPCR ( Figure 1C for representative data for CTNS -/-36). As all of these lines displayed similar phenotypes, line 36 was used for subsequent analyses (herein referred to as CTNS -/-). In addition to patient-specific lines, we also generated independent CTNS knockout (KO) lines by performing CRISPR/Cas9 gene editing in CRL1502 iPSCs 42 (Briggs et al., 2013) . Guide RNAs were used to introduce a 257 bp deletion in exon 8 and 9
of the CTNS gene, resulting in deletion of the second transmembrane domain ( Figure 1E 
CTNS-iPSCs load cystine and cysteine
Accumulation of cystine in lysosomes in all cells of the body is a hallmark of cystinosis.
Cystine was measured in cystinotic and control iPSCs by mass spectrometry, revealing 3-5 fold higher levels in CTNS -/and CTNS KO iPSCs compared to the CRL1502 control cells ( Figure   2A and B). Cysteine was also elevated ~6-7 fold in cystinotic iPSCs compared to controls ( Figure 2A and B) in agreement with observations made by others. 19 To assess whether cystine/cysteine levels were responsive to cysteamine treatment, we treated CTNS-iPSCs with 1 µM of cysteamine for 24 hrs, resulting in significant reductions in the levels of both cystine and cysteine (Figure 2A and B).
CTNS-iPSCs display enlarged lysosomes
To assess the size and distribution of lysosomes in the cystinotic iPSCs and to functionally confirm their lysosomal identity, the CTNS-iPSC lines were incubated with the Magic Red Figure 3J ). To show that this phenotype is due to loss of CYSTINOSIN, we performed rescue experiments by transfecting CTNS-iPSCs with a plasmid encoding Cystinosin-GFP. 49 Overexpression of this construct was capable of reducing the number of enlarged lysosomes to levels below that seen in control iPSCs ( Figure 2K ).
As the enlarged lysosome phenotype of CTNS-iPSCs is most likely caused by cystine accumulation, we next sought to phenocopy this using sucrose, which accumulates within the of lysosomes of normal cells 50, 51 . We treated control iPSCs with 50 mM sucrose for 24 hrs and found that this led to an increase in the number of enlarged lysosomes, similar to that seen in CTNS-iPSCs ( Figure 2L , M and N). As expeceted, sucrose had no effect on cystine loading ( Figure 2A ). Together, these observations are consistent with CTNS-iPSCs displaying an increased number of enlarged lysosomes due to cystine accumulation arising from defective CYSTINOSIN activity. In support of this, treatment of CTNS-iPSCs with 1 µM cysteamine for 24 hrs resulted in a reduction in the average number of enlarged lysosomes per cell although it did not completely rescue to control levels ( Figure 2C and E).
RNA-Seq analysis reveals differentially regulated genes in CTNS KO -iPSCs
To gain further insights into the phenotype of CTNS-iPSCs, we performed RNA-Seq to identify differentially expressed genes between CTNS KO -iPSCs and their isogenic control cells (n=4 biological repeats for each). We found a total of 12,750 differentially expressed genes with 8792 significantly up-regulated and 3958 significantly down-regulated (p < 0.05), compared to controls ( Supplemental Table S4 ). KEGG Pathway analysis revealed several significantly enriched pathways in CTNS KO -iPSCs that include the ribosome, spliceosome, proteasome, oxidative phosphorylation, protein processing in the ER and ubiquitin mediated proteolysis (cut-off p < 1x10 -6 ; Table 1 ). Interestingly, pathways linked to Huntington's, Parkinson's and Alzheimer's disease were also enriched, perhaps reflecting common features of these disorders with lysosomal storage diseases. 52 GO term enrichment analysis yielded a much more extensive list of gene sets that was more difficult to summarise (data not shown). However, in the 'Biological Process' category, we found enrichment for pathways implicated in cystinosis including autophagy, vesicle trafficking, redox homeostasis, the mTOR pathway and protein catabolism ( Table 2) .
We next examined whether some of the differentially expressed genes would have utility as molecular biomarkers of the cystinotic phenotype. From the top 50 differentially expressed genes (Supplemental Figure S2 ), we focused on DDIT3 (aka CHOP), which encodes a transcription factor belonging to the 'integrated stress response' involved in cellular adaptation to stress. 53 In addition, we identified two downstream targets of DDIT3: TRIB3, encoding a pseudokinase that acts as a negative feedback regulator of DDIT3 54 and CHAC1, encoding an enzyme that degrades glutathione. 55 Using qPCR we independently confirmed that DDIT3, TRIB3 and CHAC1 were upregulated in CTNS-iPSCs compared to control iPSCs ( Figure 3A and Supplemental Figure S1A ). To assess whether the expression of this gene triad is responsive to cysteamine, we treated CTNS-iPSCs with 1 µM cysteamine for 24 hrs and found that they decreased to near-control levels. Incubation of control iPSCs with 50 mM sucrose for 24 hrs also resulted in an up-regulation of DDIT3, TRIB3 and CHAC1, indicating that these genes, while not specific biomarkers of cystinotic cells per se, may 'read-out' lysosomal dysfunction caused by the accumulation of indigestible substrates ( Figure 3B ).
Glutathione levels are unchanged in CTNS-iPSCs
Given the role of CHAC1 in the degradation of GSH and prior reports that suggested that impaired lysosomal cystine efflux may alter GSH homeostasis, 16, 20,22,56 we examined the levels of GSH in cystinotic iPSCs by mass spectrometry. No significant difference was seen in the total amount of GSH in CTNS-iPSCs compared to controls. Furthermore, no difference was observed in the ratio of oxidized (GSSG) to reduced GSH, indicating that CTNS-iPSCs are unlikely to be under significant oxidative stress (Supplemental Figure S1C and D) .
The mTORC1 pathway appears unaffected in CTNS-iPSCs Closer scrutiny of the autophagy genes identified from the GO term analysis revealed that CTNS KO -iPSCs show a slight upregulation of MTOR as well as two of its downstream targets (ULK1 and ATG13) compared to control cells ( Figure 3C ). To assess mTORC1 activity in CTNS-iPSCs we performed western blotting for phosphorylated S6 (pS6), a downstream target of mTORC1, under basal conditions and after starvation for 60 mins, followed by refeeding. 57, 58 We found no difference in pS6 levels between the cystinotic iPSCs and control cells under basal conditions (Supplemental Figure S1F ) and unlike prior reports, 40,41 we did not detect a delay in the re-activation of mTORC1 at 2.5, 7, 12 or 15 mins following re-feeding (Supplemental Figure S1F and data not shown). Together these observations indicate that there are no significant defects in mTORC1 activity in CTNS KO -iPSCs under basal conditions or following starvation in terms of S6 phosphorylation.
Basal autophagy flux is perturbed in CTNS-iPSCs
Of the autophagy-related genes identified in the GO term analysis, we noted that there are genes involved in early through to late processes of autophagy including autophagosome formation (SQSTM1, BECLIN1, LC3B), movement (HDAC6) and tethering and fusion (RUBICON, UVRAG, VPS16, VAMP8, STX17, SNAP29; these and other selected genes are shown in Figure 3C ). In most cases, these genes are upregulated in CTNS KO -iPSCs compared to controls ( Figure 3C) . Notably, an increase in SQSTM1/p62 can be indicative of a block in autophagy flux.
To explore basal autophagy levels, we first measured the levels of the autophagosome specific protein LC3B-II by western blotting. Consistent with the RNA-Seq data, we found higher levels of LC3B-II in CTNS -/--iPSCs compared to control iPSCs, indicating either an increase in the number of autophagosomes or a decrease in autophagosome degradation ( Figure 4A ).
To quantify autophagosome and autolysosome numbers, we transfected CTNS-iPSCs and control iPSCs with a plasmid encoding the mCherry-LC3B-GFP sensor that fluorescently labels autophagosomes in yellow and autolysosomes in red 59 . Under basal conditions, CTNS -/cells were found to have a ~2.6-fold higher levels of yellow puncta (autophagosomes) compared to control iPSCs ( Figure 4B and C).
To assess the flux through the autophagy pathway, we treated CTNS-iPSCs and control iPSCs expressing the mCherry-LC3B-GFP sensor with Bafilomycin A1 (BafA1), which inhibits fusion of lysosomes with autophagosomes 60 . While BafA1 induced a 2.7-fold increase in the percentage of yellow puncta in control iPSCs compared to vehicle (DMSO) treated cells, only a slight, but non-significant increase was seen in CTNS-iPSCs ( Figure 4B , C and D). To confirm that the autophagy defect was specific to a loss of CYSTINOSIN activity we transfected CTNS -/--iPSCs with the Cystinosin-GFP plasmid, resulting in a ~1.2 fold reduction in the percentage of yellow puncta ( Figure 4E and F). Taken together, these results indicate that loss of CYSTINOSIN function in iPSCs causes an accumulation of autophagosomes under basal conditions due to reduced fusion of lysosomes with autophagosomes. We speculate that this block leads to a compensatory upregulation of numerous autophagy pathway genes, as a part of a feedback response.
The basal autophagy block in CTNS-iPSCs may be caused by the accumulation of cystine in the lysosome. To explore this, we treated control iPSCs with 50 mM sucrose for 24 hrs and then transfected them with the mCherry-LC3B-GFP sensor. We found that the percentage of yellow puncta increased 1.5-fold in sucrose loaded cells compared to control cells, indicative of a reduction in basal autophagic flux ( Figure 4G ). Given this, we next tested whether treatment with cysteamine would ameliorate the basal autophagy flux defect of CTNS-iPSCs transfected with the mCherry-LC3B-GFP sensor. Unexpectedly, we found that treating CTNS-iPSCs with 1 µM cysteamine for 24 hrs did not greatly improve basal autophagy flux ( Figure   4H and I). We conclude from these findings that the basal autophagy defect in cystinotic iPSCs is caused by a loss of CYSTINOSIN but this cannot be ameliorated by cysteamine treatment.
Basal autophagy flux defects are rescued in CTNS-iPSCs by mTORC1 inhibition
The failure of cysteamine to restore basal autophagy flux in CTNS-iPSCs may provide a rationale for why cysteamine therapy is not curative and led us to speculate that activating autophagy via mTORC1 inhibition may provide additional therapeutic benefit. To test this, we treated CTNS-iPSCs for 24 hrs with 100 nM Everolimus and examined basal autophagy flux.
We found that Everolimus restores the number of yellow puncta (autophagosomes) to control levels and correspondingly increased the number of autolysosomes, in agreement with similar results reported using Ctns -/mouse fibroblasts 33 ( Figure 4H and I). Importantly, dual treatment of 1 µM cysteamine and 100 nM Everolimus had similar effects as Everolimus alone, without any sign of combination toxicity ( Figure 4H and I).
Cystine levels remain high in CTNS-iPSCs following mTORC1 inhibition
We then assessed cystine and cysteine levels in Everolimus and combined Everolimus/cysteamine treated cells. Everolimus alone had no significant effect on cystine/cysteine levels when CTNS -/-iPSCs were treated but caused a 1.3 fold increase in CTNS KO iPSCs (Figure 2A and B) . Combination treatment decreased cystine/cysteine to levels similar to that seen with cysteamine treatment alone (Figure 2A and B) , indicating that activation of the mTORC1 pathway does not interfere with the ability of cysteamine to deplete cystine/cysteine.
mTORC1 inhibition reduces enlarged lysosomes in CTNS-iPSCs via autophagy
Next we examined the effect of Everolimus treatment on the enlarged lysosome phenotype.
We found that Everolimus reduces the average number of enlarged lysosomes to near-normal levels, making it more effective than cysteamine alone ( Figure 2C ). Combined
Everolimus/cysteamine treatment yielded intermediate results with a ~2 fold reduction compared to untreated CTNS-iPSCs, indicating that cysteamine interferes with the ability of
Everolimus to reduce the number of enlarged lysosomes ( Figure 2C ). In addition, Everolimus treatment reduced the number of enlarged lysosomes induced by sucrose-loading, suggesting that its effects on the lysosome are not specific to cystinotic cells ( Figure 2N ).
To determine if the effects of Everolimus on enlarged lysosomes was dependent on autophagy, we investigated the effects of 3-methyladenine (3-MA), an inhibitor of autophagy that acts downstream of mTORC1. 61 First, we treated control and CTNS-iPSCs for 24 hours with 30 mM of 3-MA alone. We observed a ~4-5 fold increase in the average number of enlarged lysosomes per cell in control iPSCs while levels in CTNS -/and CTNS KO iPSCs did not significantly increase further ( Figure 4J and K). Treating CTNS-iPSCs with both 3-MA and Everolimus failed to have any significant effect on the number of enlarged lysosomes ( Figure   4J and K), providing strong evidence that the effects of Everolimus are mediated via stimulation of autophagy.
Everolimus reduces expression of CHOP, TRB3, and CHAC1 in CTNS-iPSCs
We then assessed the effects of Everolimus alone and combined Everolimus/cysteamine treatment on the expression of DDIT3, TRB3, and CHAC1. In both CTNS -/and CTNS KO iPSCs, Everolimus alone and combined treatment reduced the expression levels of the gene triad to near-control levels, in keeping with the notion that these genes are providing a read-out of lysosome dysfunction in iPSCs ( Figure 3A and Supplemental Figure S1A ).
Characterisation of cystinotic kidney organoids
Having established the potential therapeutic effects of combined Everolimus/cysteamine treatment in CTNS-iPSCs, we next assessed whether these compounds would show efficacy on human cystinotic kidney tissue, using a kidney organoid protocol we recently developed 46 .
Using this approach, we matured CTNS -/-, CTNS KO and control cells into kidney organoids for 14 days 46 . Similar to our results obtained with undifferentiated CTNS-iPSCs, we found that the CTNS -/and CTNS KO organoids also display cysteine/cysteine loading but no differences in the ratio of GSH/GSSG compared to isogenic control organoids ( Figure 5A and Supplemental Figure S1E ).
At the level of light microscopy, both the CTNS -/and CTNS KO kidney organoids appear equivalent to the control organoids and we see no evidence of abnormalities such as the characteristic cystinotic 'swan neck' lesion (data not shown). However, at the ultrastructural level, we qualitatively observed the presence of numerous enlarged vacuoles in the tubules of cystinotic organoids, reminiscent of the degradative/storage-like bodies seen in CTNS-iPSCs, whereas these are rarely seen in control organoids ( Figure 5B ).
To quantify the enlarged lysosomes in cystinotic organoids, we dissociated the tissue at day 12 into single cells and then incubated them in Magic Red. We found that CTNS organoids display ~2-3 fold more enlarged lysosomes compared to control organoids ( Figure 5C and D).
To determine if basal autophagy flux is affected in CTNS kidney organoids we transfected dissociated single cells with the mCherry-LC3B-GFP sensor plasmid. We found that cystinotic kidney organoid cells display ~1.5-2-fold more autophagosomes compared to control organoid cells, consistent with a defect in basal autophagy ( Figure 5E and F).
We next assessed mRNA expression of DDIT3, TRB3, and CHAC1 in cystinotic and control kidney organoids using qPCR. We found that DDIT3 and CHAC1 were increased in cystinotic kidney organoids compared to controls ( Figure 5G and Supplemental Figure S1B ). TRB3 was not up-regulated, indicating that this gene may only be useful as a biomarker of lysosomal dysfunction in certain cell types.
We next examined the effects of single and combination treatment of cysteamine and
Everolimus on CTNS kidney organoids with respect to the phenotypes of cystine/cysteine loading, basal autophagy flux, and DDIT3, TRB3, and CHAC1 expression. To this end we treated day 13 CTNS and control kidney organoids with 1 µM cysteamine or 100 nM Everolimus and a combination of both drugs for 24 hrs. In keeping with our observations in CTNS-iPSCs, we found that cysteamine alone and when combined with Everolimus reduced cystine and cysteine levels whereas no effect was seen with Everolimus treatment alone ( Figure   5A ). Both cysteamine or Everolimus alone and combined treatments reduced the numbers of enlarged lysosomes ( Figure 5C and D) . Everolimus alone activated autophagy, as did combined treatment, but cysteamine alone had no effect ( Figure 5E and F) . Finally, qPCR analysis of the treated kidney organoids showed that the expression levels of DDIT3 and CHAC1 were normalised to near-control values in response to cysteamine alone and combined treatments, as well as Everolimus alone treatment in the case of CTNS -/organoids. However, Everolimus alone treatment had only modest effects on reducing DDIT3 and CHAC1 in CTNS KO organoids ( Figure 5G and Supplemental Figure S1B ).
Discussion:
In this report we generated new human models of cystinosis in the form of cystinotic iPSCs and kidney organoids and demonstrated a phenotype characterized by cystine and cysteine loading, enlarged lysosomes, altered gene expression and defective basal autophagy. Using this unique human-based platform we tested the therapeutic effects of cysteamine and Everolimus and found that a combination therapy was able to mitigate all of the observed cystinotic phenotypes in a beneficial and effective manner. Furthermore, these models have the potential to be used as a preclinical model for testing other therapeutics as well as a novel tool to deepen our understanding of the pathogenic mechanisms at play in cystinosis.
Of the defects observed in cystinotic iPSCs and kidney organoids, the block in basal autophagy flux appears most significant as it is the only phenotype that cysteamine is unable to rescue.
The finding that the number of autophagosomes in CTNS-iPSCs does not significantly increase in the presence of BafA1 may indicate an accumulation of autophagosomes under basal conditions due to a defect in lysosomal fusion. Although CYSTINOSIN is a H + driven transporter 49 and lysosomal pH is important for lysosomal fusion 62 previous reports have shown that the pH of cystinotic lysosomes is normal. 12 Thus, the underlying cause for the failure of lysosomes to fuse with autophagosomes remains unclear. There are a number of protein complexes that coordinate this fusion and a requirement for the physical movement of both autophagosomes and lysosomes. Therefore, is possible that one or more of these processes is affected in cystinotic cells. 63 The observation that sucrose loading induces the equivalent phenotype in non-cystinotic iPSCs and that other lysosomal storage diseases show basal autophagy flux defects points to the intralysosomal accumulation of indigestible material as a generic cause of the flux defect. [64] [65] [66] [67] Our finding that CTNS-iPSCs upregulate a number of genes in the autophagy pathway suggests that compromised basal autophagy leads to the activation of transcriptional feedback mechanisms to compensate for the reduced flux.
If cystine accumulation impairs autophagosome-lysosome fusion and reduces basal autophagy flux then cysteamine treatment would have been expected to have rescued the basal autophagy phenotype of CTNS-iPSCs. Interpreting the failure of cysteamine to restore basal autophagy is complicated by a report showing that cysteamine treatment of HeLa cells under basal conditions affects the autophagy pathway in two places: first by acting early to induce autophagosome formation but then acting later to inhibit autolysosome maturation 68 . Thus, it is likely that while cysteamine may restore lysosomal functionality in cystinotic cells by depleting cystine, its independent inhibitory effects on autolysosome maturation induces an equivalent block in basal autophagy flux. This additional activity of cysteamine may be related to its antioxidant properties as reactive oxygen species are known to regulate autophagy via the redox-modification of several autophagy components and antioxidants can inhibit basal autophagy. 69, 70 Several mouse studies have demonstrated a critical role for basal autophagy in maintaining proximal tubule function and support the notion that continued renal dysfunction in cysteamine-treated cystinosis patients is linked to a failure to restore basal autophagy.
Specifically, it has been shown that blocking autophagy in kidney cells in vivo and in vitro
under nutrient replete conditions results in the accumulation of degradative vacuoles, deformed mitochondria, and p62-and ubiquitin-positive inclusion bodies. [71] [72] [73] Similar observations have been reported for kidney biopsies and urinary cells from cystinotic patients and in primary proximal tubule cells from the Ctns -/mouse. 26, 27, 71, 74 Consistent with one of the functions of basal autophagy being the removal of damaged mitochondria, work using cystinotic mouse primary proximal tubule cells has led to a model in which defective autophagy-mediated clearance of damaged mitochondria (mitophagy) causes oxidative stress and triggers renal epithelial cell dysfunction. 27 While we have not detected an increased level of oxidative stress or deformed mitochondria in CTNS-iPSCs (unpublished observations), this may be due to iPSCs relying on glycolysis rather than oxidative phosphorylation for their energy needs. 75 By contrast, proximal tubule cells contain a large quantity of mitochondria in order to drive membrane transport processes and it is reasonable to conclude that these cells would be highly dependent on efficient basal autophagy for mitochondrial quality control. Other tissues such as hepatocytes, neurons, heart and skeletal muscle have also been found to be dependent on basal autophagy 76 and although neural and muscle tissues are eventually affected in individuals with cystinosis, it is the proximal tubule that is affected early in the disease. One explanation for this is that the lysosomal system of proximal tubule cells is under a high degradative load due to the uptake and degradation of albumin and other plasma proteins harbouring disulphide bonds. 77, 78 Thus, the level of lysosomal cystine accumulation and the resulting basal autophagy dysfunction (assuming it is proportional to cystine load) would be expected to be pronounced in cystinotic proximal tubule cells in comparison to other tissues.
Prior studies using immortalized mouse and human proximal tubule cells found a transportindependent role for CYSTINOSIN that implicated it in the positive regulation of mTORC1. 40, 41 Despite detecting a slight upregulation of MTOR RNA and two of its downstream targets (ULK1 and ATG13) in CTNS-iPSCs, we found no evidence to indicate that mTORC1 protein activity is altered. Similarly, no effect in mTORC1 activity was found in mouse cystinotic fibroblasts. 33 At this stage, the cause for these discrepancies is not known but may be related to metabolic differences between cell lines. Alternatively, there may be confounding influences of the viral antigens used for immortalization as these can influence mTORC1 levels. 79 We found that inhibiting mTORC1 with Everolimus was capable of overcoming the basal autophagy block, presumably via activation of the stress-induced autophagy pathway.
Everolimus also reduced the frequency of enlarged lysosomes in CTNS-iPSCs and because this effect was abrogated by 3-MA it is likely that these structures are being cleared by autophagy.
This notion is in-line with the discovery that autophagy is involved in the removal/recycling of aged and dysfunctional lysosomes (lysophagy) in order to prevent cell damage caused by the leakage of hydrolytic enzymes 80, 81 . At this stage it remains unclear if the basal autophagy block seen in cystinotic cells also results in a lysophagy defect. However, it is an attractive hypothesis as large lysosomes are particularly vulnerable to rupture and some cystinotic cells have been found to be sensitive to apoptosis. 14, 24, 25, 82, 83 Interestingly, if dysfunctional lysosomes are not removed, the total number of lysosomes remains unchanged, even if some of them are nonfunctional. 81 Thus, lysosome quality control is critical for maintaining cellular degradative capabilities and therefore lysophagy defects could contribute additional stress to cystinotic proximal tubule cells.
At present, mTOR inhibitors are used in the clinic as immunosuppressants and as treatments for some cancers. 84, 85 Our work suggests that Everolimus, and related Rapamycin derivatives, may also have therapeutic potential to treat cystinosis. This notion is consistent with studies of the lysosomal disorders mucopolysaccharidosis and Niemann-Pick disease, where overcoming a block in autophagic flux improves cell viability. 64, 86, 87 In the case of Niemann-Pick disease Type C, a combination therapy of low dose hydroxypropyl-b-cyclodextrin (which depletes the cholesterol accumulating in the lysosome) coupled with an autophagy stimulator has been proposed 88 . We have arrived at the same conclusion with our findings and hypothesize that dual treatment of cystinotic individuals with cysteamine and an autophagy inducer such as Everolimus will improve long-term outcomes. The next step in testing this hypothesis requires animal studies, although this will be challenging with the current Ctns -/mouse model as it does not fully recapitulate the progression of the human disease and shows a relatively late chronic kidney failure phenotype. 14, 89 In considering these experiments, careful attention will need to be given to finding the lowest effective dosing schedule, as mTOR inhibitors have metabolic 
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